Joachim Drevs

from Wikipedia, the free encyclopedia

Joachim Drevs (born August 16, 1966 in Konstanz ) is a German specialist in internal medicine with a focus on hematology and oncology , as well as a professor at the Freiburg University Clinic and former head of the health center at the Tübingen University Clinic .

Life

Drevs began studying human medicine at the Georg-August University in Göttingen in 1987 . There he passed his state examination in 1994 and received his doctorate in the same year under Clemens Unger ; He received his license to practice medicine in March 1995. This was followed by positions abroad at the Bircher Clinic Foundation, Switzerland, at the Mount Sinai Hospital in New York and at the clinic of Sefako Makgatho Health Sciences University , South Africa , always with a focus on oncology. In 2005 he completed his habilitation at the Freiburg University Clinic , and in 2009 he was appointed as an adjunct professor there . Drevs now heads a practice clinic for integrative oncology near Braunschweig with a branch on Mallorca .

Clinical focus

Drevs set up one of the first university health centers in Germany in Tübingen, where disease treatment and health promotion are offered and practiced together. His focus was the implementation of new innovative therapeutic approaches from the research of cancer diseases the clinical application.

research

Drevs conducted research on angiogenesis and was involved in the creation of a new group of drugs for the treatment of cancer patients, Molecular Targeted Therapy . There are research projects u. a. with James F. Holland , Gerd Nagel , Hubert Blum.

Academic tasks at national and university level

  • Ethics Center of the University of Zurich, member until 1996
  • Working Group for Internal Oncologists (AIO), Working Groups "Translational Research", "Drug Development", "Oncological Rehabilitation"

Memberships in scientific associations

Web links

Individual evidence

  1. Jump up ↑ Effects of PTK787 / ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model. Joachim Drevs, Inga Hofmann, Harald Hugenschmidt, Christine Wittig, Helmut Madjar, Marianne Müller, Jeanette Wood, Georg Martiny-Baron, Clemens Unger and Dieter Marmé. Cancer Res September 1,2000 (60) (17) 4819-4824;
  2. ↑ Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors. Joachim Drevs, Patrizia Siegert, Michael Medinger, Klaus Mross, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert Blum, Jane Robertson, Juliane M. Jürgensmeier, Thomas A. Puchalski, Helen Young, Owain Saunders, and Clemens Unger. Journal of Clinical Oncology 2007 25:21, 3045-3054;
  3. ↑ PTK787 / ZK 222584, a Specific Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging. Joachim Drevs, Ralph Müller-Driver, Christine Wittig, Stefan Fuxius, Norbert Esser, Harald Hugenschmidt, Moritz A. Konerding, Peter R. Allegrini, Jeanette Wood, Jürgen Hennig, Clemens Unger and Dieter Marmé. Cancer Res July 15 2002 (62) (14) 4015-4022;
personal data
SURNAME Drevs, Joachim
BRIEF DESCRIPTION German hematologist, oncologist and university professor
DATE OF BIRTH August 16, 1966
PLACE OF BIRTH Constancy